Investigating why African Americans have higher rates of ameloblastoma recurrence
Biological Indicators of Racial Disparity in Ameloblastoma Recurrence
This study is looking at why ameloblastoma comes back more often in African Americans and aims to find specific genetic clues that could help predict this, using mice to learn more about how these tumors grow and survive, so we can improve treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10993656 on NIH RePORTER |
What this research studies
This research focuses on understanding the biological factors that contribute to the higher recurrence rates of ameloblastoma in African Americans compared to other racial groups. It aims to identify specific biological markers that could predict recurrence by studying genetic mutations, particularly in the BRAF gene, and their relationship with autophagy mechanisms in tumor cells. The researchers will utilize a mouse model to observe the behavior of these tumors and the role of autophagic markers in tumor survival and invasiveness. By uncovering these mechanisms, the study seeks to provide insights that could lead to improved treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American individuals diagnosed with ameloblastoma.
Not a fit: Patients of other racial backgrounds or those without a diagnosis of ameloblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better predictive markers for ameloblastoma recurrence, ultimately improving treatment outcomes for African American patients.
How similar studies have performed: While there has been research on ameloblastoma, this specific focus on racial disparities and autophagy mechanisms is relatively novel and has not been extensively tested.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Akintoye, Sunday O — University of Pennsylvania
- Study coordinator: Akintoye, Sunday O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.